Patents by Inventor Caly Chien

Caly Chien has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Androgen Receptor Inhibitors For The Treatment Of Non-Metastatic Castration-Resistant Prostate Cancer In Subjects With Severe Hepatic Impairment
    Publication number: 20230338351
    Abstract: Described herein are methods of treating non-metastatic castration-resistant prostate cancer in subjects with severe hepatic impairment with androgen receptor inhibitors, including but not limited to, 4-[7-(6-cyano-5-trifluoromethylpyridin-3-yl)-8-oxo-6-thioxo-5,7-diazaspiro[3.4]oct-5-yl]-2-fluoro-N-methylbenzamide.
    Type: Application
    Filed: June 15, 2023
    Publication date: October 26, 2023
    Inventors: Caly Chien, Peter Hellemans, Alex Yu
  • Androgen receptor inhibitors for the treatment of non-metastatic castration-resistant prostate cancer in subjects with severe hepatic impairment
    Patent number: 11723898
    Abstract: Described herein are methods of treating non-metastatic castration-resistant prostate cancer in subjects with severe hepatic impairment with androgen receptor inhibitors, including but not limited to, 4-[7-(6-cyano-5-trifluoromethylpyridin-3-yl)-8-oxo-6-thioxo-5,7-diazaspiro[3.4]oct-5-yl]-2-fluoro-N-methylbenzamide.
    Type: Grant
    Filed: November 4, 2020
    Date of Patent: August 15, 2023
    Assignee: Aragon Pharmaceuticals, Inc.
    Inventors: Caly Chien, Peter Hellemans, Alex Yu
  • ANTI-ANDROGENS FOR THE TREATMENT OF PROSTRATE CANCER
    Publication number: 20210137903
    Abstract: Disclosed herein are pharmaceutical compositions and methods of treating prostate cancer including castrate resistant prostate cancer, metastatic castration resistant prostate cancer and non-metastatic castration resistant prostate cancer with an approved drug product containing an anti-androgen selected from the group consisting of enzalutamide, apalutamide and darolutamide.
    Type: Application
    Filed: July 16, 2020
    Publication date: May 13, 2021
    Inventors: Caly Chien, Maura Erba, Meike Van Uffel, Alex Yu, Anasuya Hazra
  • ANDROGEN RECEPTOR INHIBITORS FOR THE TREATMENT OF NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER IN SUBJECTS WITH SEVERE HEPATIC IMPAIRMENT
    Publication number: 20210128541
    Abstract: Described herein are methods of treating non-metastatic castration-resistant prostate cancer in subjects with severe hepatic impairment with androgen receptor inhibitors, including but not limited to, 4-[7-(6-cyano-5-trifluoromethylpyridin-3-yl)-8-oxo-6-thioxo-5,7-diazaspiro[3.4]oct-5-yl]-2-fluoro-N-methylbenzamide.
    Type: Application
    Filed: November 4, 2020
    Publication date: May 6, 2021
    Inventors: Caly Chien, Peter Hellemans, Alex Yu